This report analyzes the worldwide markets for Cardiac Biomarkers in Millions of US dollars. The market is analyzed by Location-wise (Clinical Laboratory Testing, and Point-of-Care Testing) and by Assay type-wise (Acute Myocardial Infarction (AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)).

The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual forecasts are provided for each region for the period of 2006 through 2015.

A five-year historic analysis is also provided for these markets. The report profiles 78 companies including many key and niche players worldwide such as Abbott Diagnostics, Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomerieux, Inverness Medical Innovations, Inc., LifeSign LLC, Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Oxis International, Inc., Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.